- Home
- BRN vs KPRX Comparison
BRN vs KPRX Comparison
Compare BRN & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRN
- KPRX
- Stock Information
- Founded
- BRN 1956
- KPRX 1998
- Country
- BRN United States
- KPRX United States
- Employees
- BRN N/A
- KPRX N/A
- Industry
- BRN Oil & Gas Production
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BRN Energy
- KPRX Health Care
- Exchange
- BRN Nasdaq
- KPRX Nasdaq
- Market Cap
- BRN 11.4M
- KPRX 9.2M
- IPO Year
- BRN N/A
- KPRX N/A
- Fundamental
- Price
- BRN $1.16
- KPRX $2.63
- Analyst Decision
- BRN
- KPRX Strong Buy
- Analyst Count
- BRN 0
- KPRX 1
- Target Price
- BRN N/A
- KPRX $10.00
- AVG Volume (30 Days)
- BRN 29.6K
- KPRX 26.7K
- Earning Date
- BRN 08-13-2025
- KPRX 11-07-2025
- Dividend Yield
- BRN N/A
- KPRX N/A
- EPS Growth
- BRN N/A
- KPRX N/A
- EPS
- BRN N/A
- KPRX N/A
- Revenue
- BRN $18,073,000.00
- KPRX N/A
- Revenue This Year
- BRN N/A
- KPRX N/A
- Revenue Next Year
- BRN N/A
- KPRX N/A
- P/E Ratio
- BRN N/A
- KPRX N/A
- Revenue Growth
- BRN N/A
- KPRX N/A
- 52 Week Low
- BRN $1.08
- KPRX $2.25
- 52 Week High
- BRN $2.40
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- BRN 51.10
- KPRX 45.30
- Support Level
- BRN $1.08
- KPRX $2.58
- Resistance Level
- BRN $1.19
- KPRX $2.74
- Average True Range (ATR)
- BRN 0.05
- KPRX 0.11
- MACD
- BRN 0.00
- KPRX -0.01
- Stochastic Oscillator
- BRN 62.50
- KPRX 15.63
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.